Your present location:About Us >> Research and Development

Overview of Research Institute

Founded in 1998, Sichuan Kelun Pharmaceutical Research Institute is located in the Land of Abundance – Chengdu of Sichuan. The newly built R & D building of the institute was put into use from May 2013, covering an area of 24,000m2, with a total investment of over RMB one hundred million. The company now has over 340 pharmaceutical researchers, and 18 dedicated technical departments ranging from selection of projects and cooperation, development of generic and innovative drugs, pharmacology and clinical research, to the project registration and comprehensive management, built a complete R & D system from APIs synthesis to the project application. It establishes an organization system of Central Research Institute (Chengdu) as the core, Southern Research Institute (Suzhou) / Northern Research Institute (Tianjin), Overseas Research Institute, as branches, and building all subsidiaries’ R & D teams, and plans to expand the team to about 1000 employees and build a first-class R & D team consisting of excellent scientists of various fields who are committed to innovation and hi-tech pharmaceutical research.

Technological innovation is the core competence of a company. Under the new situation, Kelun has re-positioned its product development and technological innovation strategically, adopted the development strategy driven by "three engines", in order to form a powerful layout for IV Solution and non-IV Solution segments and to build an invincible strength in the market. The three engines are:

“Engine 1" - continue to strengthen the R & D efforts in the high-end infusion product line and further strengthen the high value-added infusion. At present, Kelun’s product line covers such fields as expansion of blood volume, electrolyte, anesthesia, parenteral nutrition, anti-tumor and contrast agents, etc, and is extending to dual-and triple-chamber bags in packing.

"Engine 2" - strengthen the construction of the whole industry chain for antibiotic products, improve antibiotic product lines, to gain a stronghold globally in the field of antibiotics.

"Engine 3" - promote high-end drug product lines, carry out R & D of hi-tech drugs, and emphasize the development of early generic drugs, first-time generic drugs, novel drug delivery systems, innovative small molecules and biological drugs badly required in clinical practice.

Sichuan Kelun Pharmaceutical Research Institute has established a number of national, provincial and municipal innovation platforms, including State-Level Enterprise Technology Center, National Regional United Engineering Laboratory, National Engineering Research Center of Large Volume Parenteral Preparations, National Postdoctoral Workstation, Kelun Innovative Drug Incubator Base etc. The construction of these platforms is a good foundation for innovation of enterprises, making the company capable of developing drugs which take the lead in the country.

In addition to Sichuan Kelun Pharmaceutical Research Institute, Kelun has started the founding of its research branches in Tianjin and Suzhou; meanwhile, it is under preparation of building a wholly owned subsidiary in the United States, in order to constantly introduce high-end talents and rapidly raise the R & D level. At the same time, the institute actively carries out extensive exchanges and cooperation with universities and research institutes and has set up extensive, in-depth and long-term partnerships with more than 20 medical research institutes, including Peking University, China Pharmaceutical University, Shenyang Pharmaceutical University, East China University of Science and Technology, Sichuan University, Jiangxi University of Traditional Chinese Medicine, Chengdu University of TCM, Sichuan Academy of Chinese Medicine Sciences, Sichuan Industrial Institute of Antibiotic, etc., and makes full use of knowledge alliances to promote R & D strength of Kelun Pharmaceutical.